Claims for Patent: 11,944,690

« Back to Dashboard

Summary for Patent: 11,944,690

Title:	Formulation of contrast media and process of preparation thereof
Abstract:	The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.
Inventor(s):	Stephan Holzschuh, Thomas Frenzel, Gregor Jost, Jessica Lohrke, Wolfgang Ebert, Thomas Brumby, Wolfgang Halfbrodt
Assignee:	Bayer AG , Bayer Pharma AG
Application Number:	US17/295,647
Patent Claims:	1. A liquid pharmaceutical formulation comprising a DO3A -derived tetra-chelate of general formula (I): wherein R1 represents a group selected from: wherein group * indicates the point of attachment of the group with the rest of the molecule, R2, R3, and R4 independently of each other represents a hydrogen atom or a group selected from: C1-C6-alkyl, C3-C6-cycloalkyl, (C1-C2-alkoxy)-(C2-C3-alkyl)-, and phenyl, wherein the C1-C6-alkyl group is optionally substituted, identically or differently, with a phenyl substituent, wherein the phenyl substituent is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, and wherein the phenyl group is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, R5 represents a group selected from: C1-C6-alkyl, C3-C6-cycloalkyl, (C1-C2-alkoxy)-(C2-C3-alkyl)- and phenyl, wherein the C1-C6-alkyl group is optionally substituted, identically or differently, with a phenyl substituent, wherein the phenyl substituent is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, and wherein the phenyl group is optionally substituted, one, two, or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, X represents a group C(═O)OH or C(═O)O−, and M represents Gd3+, or a stereoisomer, a tautomer or a salt thereof, or a mixture of same, wherein the formulation further comprises a pharmaceutically acceptable solvent; and at least one compound capable of forming a chelate with a free paramagnetic metal ion M, wherein the at least one compound is Ca-BT-DO3A (Calcobutrol) in a concentration range of 0.002% to 5% mol/mol (inclusive), measured as a proportion relative to a total concentration of the Gd3− ion in the formulation, wherein the DO3A-derived tetra-chelate has a concentration in the formulation in a range of 60 to 750 mmol paramagnetic Gd3−/L (inclusive). 2. The formulation according to claim 1, wherein R2 represents a hydrogen atom or a methyl group, R3 and R4 each represent a hydrogen atom, and R5 represents a group selected from methyl, ethyl, isopropyl, 2-methylpropyl, benzyl, cyclopropyl, cyclopentyl, cyclohexyl, 2-methoxyethyl, 2-ethoxyethyl, and phenyl. 3. The formulation according to claim 1, wherein the DO3A -derived tetra-chelate of formula (I) has a structure selected from a chelate of formulae (I-a), (I-b), and (I-c): or a stereoisomer, a tautomer or a salt thereof, or a mixture of same. 4. The formulation according to claim 3, wherein the DO3A -derived tetra-chelate of formula (I) has the formula (I-a): or a stereoisomer, a tautomer or a salt thereof, or a mixture of same. 5. The formulation according to claim 4, wherein the DO3A -derived tetra-chelate of formula (I-a) has a stereochemistry at the chiral carbon of the four methyl substituents selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof. 6. The formulation according to claim 1, wherein the formulation has a concentration of a free paramagnetic Gd3+ of less than or equal to 5 ppm (m/v). 7. The formulation according to claim 1, wherein the formulation has a pH in a range of 4.5 to 8.5 (inclusive). 8. The formulation according to claim 1, further comprising a buffer, wherein the buffer is selected from the group consisting of a citrate buffer, a lactate buffer, an acetate buffer, a tartrate buffer, a malate buffer, a maleate buffer, a phosphate buffer, a succinate buffer, an ascorbate buffer, a carbonate buffer, a trometamol (TRIS, 2-amino-2-(hydroxymethyl)propane-1,3-diol) buffer, an HEPES (2-[4-(2-hydroxyethyl)-1-piperazine] ethanesulfonic acid) buffer, an MES (2-morpholinoethanesulfonic acid) buffer, and mixtures thereof. 9. A process for preparing a liquid pharmaceutical formulation, the process comprising the following steps: providing a pharmaceutically acceptable solvent; dissolving a DO3A-derived tetra-chelate of formula (I): wherein R1 represents a group selected from: wherein group * indicates the point of attachment of the group with the rest of the molecule, R2, R3, and R4 independently of each other represents a hydrogen atom or a group selected from: C1-C6-alkyl, C3-C6-cycloalkyl, (C1-C2-alkoxy)-(C2-C3-alkyl)-, and phenyl, wherein the C1-C6-alkyl group is optionally substituted, identically or differently, with a phenyl substituent, wherein the phenyl substituent is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, and wherein the phenyl group is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, R5 represents a group selected from: C1-C6-alkyl, C3-C6-cycloalkyl, (C1-C2-alkoxy)-(C2-C3-alkyl)- and phenyl, wherein the C1-C6-alkyl group is optionally substituted, identically or differently, with a phenyl substituent, wherein the phenyl substituent is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, and wherein the phenyl group is optionally substituted, one, two, or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, X represents a group C(═O)OH or C(═O) O31, and M represents Gd3+; or a stereoisomer, a tautomer or a salt thereof, or a mixture of same, in the pharmaceutically acceptable solvent in in sufficient amount to produce a solution of the formulation having a concentration of DO3A-derived tetra-chelate of formula (I) in a range of 60 to 750 mmol paramagnetic Gd3− ion/L (inclusive), and dissolving at least one compound capable of forming a chelate with Gd3+ in sufficient amount to produce a solution having a concentration in a range of 0.002% to 5% mol/mol (inclusive) with reference to the total concentration of the Gd3+ ion , wherein the compound capable of forming a chelate with Gd3+ is Ca-BT-DO3A (Calcobutrol). 10. The process according to claim 9, further comprising one or more additional steps selected from the group consisting of: dissolving a buffer in the pharmaceutically acceptable solvent or the solution, thereby obtaining a buffered solution and adjusting the pH of the buffered solution to a pH in a range of 7.6 to 8.2 (inclusive); dissolving the Ca-BT-DO3A (Calcobutrol) in the solution; dissolving an isotonicity agent in the solution; adjusting the pH of the solution to a pH in a range of 4.5 to 8.5 (inclusive); adjusting the concentration of the DO3A-derived tetra-chelate of the formula (I) by addition of an additional amount of the pharmaceutically acceptable solvent; and sterilizing the solution. 11. A process for preparing a liquid pharmaceutical formulation, the process comprising the following steps: providing a pharmaceutically acceptable solvent; dissolving Ca-BT-DO3A (Calcobutrol) in the pharmaceutically acceptable solvent; and dissolving a DO3A-derived tetra-chelate of formula (I): wherein R1 represents a group selected from: wherein group * indicates the point of attachment of the group with the rest of the molecule, R2, R3, and R4 independently of each other represents a hydrogen atom or a group selected from: C1-C6-alkyl, C3-C6-cycloalkyl, (C1-C2-alkoxy)-(C2-C3-alkyl)-, and phenyl, wherein the C1-C6-alkyl group is optionally substituted, identically or differently, with a phenyl substituent, wherein the phenyl substituent is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, and wherein the phenyl group is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, R5 represents a group selected from: C1-C6-alkyl, C3-C6-cycloalkyl, (C1-C2-alkoxy)-(C2-C3-alkyl)- and phenyl, wherein the C1-C6-alkyl group is optionally substituted, identically or differently, with a phenyl substituent, wherein the phenyl substituent is optionally substituted, one, two or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, and wherein the phenyl group is optionally substituted, one, two, or three times, identically or differently, with a group selected from a halogen atom, C1-C3-alkyl, C1-C3-haloalkyl, and C1-C3-alkoxy, X represents a group C(═O)OH or C(═O)O−, and M represents Gd3+; or a stereoisomer, a tautomer or a salt thereof, or a mixture of same, in the pharmaceutically acceptable solvent in sufficient amount to produce a final solution having a formulation having a concentration of the DO3A-derived tetra-chelate of formula (I) in a range of 1 to 1000 mmol Gd3+/L (inclusive), and wherein the Ca-BT-DO3A is dissolved in the pharmaceutically acceptable solvent in sufficient amount to produce a solution having a concentration in a range of 0.002% to 5% mol/mol (inclusive) with reference to the total concentration of the Gd3+ ion. 12. The process according to claim 11, further comprising: dissolving an amount of the Ca-BT-DO3A (Calcobutrol) in the range of 0.002% to 5% mol/mol (inclusive) with reference to the total concentration of the Gd3+ in the formulation in the pharmaceutically acceptable solvent to form a first solution; and dissolving the DO3A-derived tetra-chelate of formula (I) in the first solution in sufficient amount to produce a final solution having a liquid pharmaceutical formulation having a concentration of the DO3A-derived tetra-chelate of formula (I) in a range of 1 mmol paramagnetic metal ion/L to 1000 mmol Gd3+/L (inclusive). 13. The process according to claim 11, wherein the DO3A-derived tetra-chelate of formula (I) is a Gd4-DO3A-derived tetra-chelate having a formula (I-a): or a stereoisomer, a tautomer or a salt thereof, or a mixture of same, wherein the Gd4-DO3A-derived tetra-chelate of formula (I-a) is dissolved in sufficient amount to produce a liquid pharmaceutical formulation having a concentration of the Gd4-DO3A-derived tetra-chelate of formula (I-a) in the range of 1 mmol Gd3+/L to 1000 mmol Gd3+/L (inclusive). 14. The process according to claim 12, wherein dissolving an amount of the CaBT-DO3A (Calcobutrol) comprises: dissolving an amount of the Ca-BT-DO3A in the range of 0.002% to 5% mol/mol (inclusive) with reference to the total concentration of the Gd3+ ion in the formulation in the pharmaceutically acceptable solvent or an aqueous buffer solution to provide a first solution.